BRCA1 and invasive breast carcinoma: Since patients with germline PVs in BRCA1/2 and residual invasive breast cancer or a CPS + EG score of 3 or higher after having received neoadjuvant chemotherapy clearly benefit from a 12 month adjuvant therapy with the PARP-inhibitor Olaparib, genetic analysis of all patients eligible for postneoadjuvant PARPi-therapy seems mandatory.